|
1. Adan A, Alizada G, Kiraz Y, et al. Flow cytometry: basic principles and applications. Crit Rev Biotechnol 2017; 37: 163-76. doi: 10.3109/07388551.2015.1128876. 2. Aghaabbasi K, Hassani Kumleh H, Askari N, et al. Anticancer activity of Blepharis persica seed hydroalcoholic extract on (MCF-7) human breast cancer and (LNCaP) prostate cancer cell lines and its synergistic effect with doxorubicin. JCT 2018; 9: 206-21. doi: 10.52547/JCT.9.3.206. 3. Isetta AM, Fornasiero MC, Ferrari M, Trizio D. Immunosuppressive activity of 4'-iodo-4'-deoxy-doxorubicin on humoral and cell mediated immune responses in mice: comparison with doxorubicin. Int J Immunopharmacol 1990; 12: 665-73. doi: 10.1016/0192-0561(90)90104-u. 4. Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006;127: 905-15. doi: 10.1016/j.cell.2006.0 9.042. 5. Asadi M, Taghizadeh S, Kaviani E, et al. Caspase-3: Structure, function, and biotechnological aspects. Biotechnol Appl Biochem 2022; 69:1633- 45. doi: 10.1002/bab.2233. 6. Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides 2015; 72: 4-15. doi: 10.1016/j.peptides.2015.04.012. 7. Yousefi Sadeghloo A, Khorsandi K, Kianmehr Z. Synergistic effect of photodynamic treatment and doxorubicin on triple negative breast cancer cells. Photochem Photobiol Sci 2020; 19:1580-9. doi: 10.1039/d0pp00132e. 8. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther 2015; 14: 769-78. doi: 10.1158/1535-7163.MCT-14-0926. 9. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019; 120: 6-15. doi: 10.1038/s41416-018-0328-y. 10. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365-72. doi: 10.1093/jnci/94.18.1365. 11. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 2020; 21:3233. doi: 10.3390/ijms21093233. 12. Chen S, Lv M, Fang S, et al. Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes. Int J Biol Macromol 2018; 113: 1182-7. doi: 10.1016/j.ijbiomac.2018.02.034. 13. Yang CY, Liu HW, Tsai YC, Tseng JY, Liang SC, Chen CY, et al. Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer. Cancer Biol Ther 2015;16: 1641-50. doi:10.1080/15384047.2015.1095397. 14. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 2016; 539:443-7. doi: 10.1038/nature20554. 15. De Vera AA, Gupta P, Lei Z, et al. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Lett 2019; 442:91-103. doi: 10.1016/j.canlet.2018.10.020. 16. Dobosz P, Stępień M, Golke A, Dzieciątkowski T. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. Int J Mol Sci 2022;23: 2847. doi: 10.3390/ijms23052847. 17. Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol 2022; 221: e202201159. doi: 10.1083/jcb.202201159. 18. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020; 5:28. doi: 10.1038/s41392-020-0134-x. 19. Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget 2015;6: 41600-19.doi: 10.18632/oncotarget.6113. 20. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int J Mol Sci 2021; 22:12827. doi: 10.3390/ijms222312827. 21. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J Drug Target 2011; 19:281-92. doi: 10.3109/1061186X.2010.499463. 22. Gibbert K, Schlaak JF, Yang D, et al. IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol 2013; 168: 1048-58.doi: 10.1111/bph.12010. 23. Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, et al. Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen. Am J Reprod Immunol 2011; 65: 597-609. doi: 10.1111/j.1600-0897.2010.00968. x. 24. Harshitha R, Arunraj DR. Real-time quantitative PCR: A tool for absolute and relative quantification. Biochem Mol Biol Educ 2021; 49: 800-812. doi: 10.1002/bmb.21552. 25. Hashimoto N, Nagano H, Tanaka T. The role of tumor suppressor p53 in metabolism and energy regulation, and its implication in cancer and lifestyle-related diseases. Endocr J 2019; 66:485-96. doi: 10.1507/endocrj. EJ18-0565. 26. Hayrapetyan H, Tran T, Tellez-Corrales E, Madiraju C. Enzyme-Linked Immunosorbent Assay: Types and Applications. Methods Mol Biol 2023; 2612: 1-17.doi: 10.1007/978-1-0716-2903-1_1. 27. Hong DS, Postow M, Chmielowski B, et al. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res 2023;29: 2210-19. 28. Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, Liu W, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer 2022; 21:45. doi: 10.1186/s12943-022-01515-x. 29. Huo W, Yang X, Wang B, Cao L, Fang Z, Li Z, et al. Biomineralized hydrogel DC vaccine for cancer immunotherapy: a boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. Biomaterials 2022; 288: 121722. doi: 10.1016/j.biomaterials.2022.121722. 30. Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci 2020; 25:1058-109. doi: 10.2741/4847. 31. Jinmiao Lu, Nana Wei, Shilan Zhu, et al. Exosomes Derived from Dendritic Cells Infected with Toxoplasma gondii Show Antitumoral Activity in a Mouse Model of Colorectal Cancer. Front Oncol 2022; 12: 899737.doi: 10.3389/fonc.2022.899737. 32. Jozefczuk J, Adjaye J. Quantitative real-time PCR-based analysis of gene expression. Methods Enzymol 2011;500: 99-109. doi: 10.1016/B978-0-12-385118-5.00006-2. 33. Kaneda MM, Messer KS, Ralainirina N, et al, PI3Kγ is a molecular switch that controls immune suppression. Nature 2016; 539: 437- 42.doi: 10.1038/nature19834. 34. Ling SP, Ming LC, Dhaliwal JS, et al. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. Cancers (Basel) 2022; 14:5205. doi: 10.3390/cancers14215205.
|
